JP2024516320A5 - - Google Patents

Info

Publication number
JP2024516320A5
JP2024516320A5 JP2023568549A JP2023568549A JP2024516320A5 JP 2024516320 A5 JP2024516320 A5 JP 2024516320A5 JP 2023568549 A JP2023568549 A JP 2023568549A JP 2023568549 A JP2023568549 A JP 2023568549A JP 2024516320 A5 JP2024516320 A5 JP 2024516320A5
Authority
JP
Japan
Prior art keywords
sequence
amino acid
seq
chain shown
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516320A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/091187 external-priority patent/WO2022233320A1/zh
Publication of JP2024516320A publication Critical patent/JP2024516320A/ja
Publication of JP2024516320A5 publication Critical patent/JP2024516320A5/ja
Pending legal-status Critical Current

Links

JP2023568549A 2021-05-07 2022-05-06 Fc受容体への結合が改変されたFc変異体 Pending JP2024516320A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110495363 2021-05-07
CN202110495363.7 2021-05-07
CN202210436873 2022-04-25
CN202210436873.1 2022-04-25
PCT/CN2022/091187 WO2022233320A1 (zh) 2021-05-07 2022-05-06 与Fc受体结合改变的Fc突变体

Publications (2)

Publication Number Publication Date
JP2024516320A JP2024516320A (ja) 2024-04-12
JP2024516320A5 true JP2024516320A5 (cg-RX-API-DMAC7.html) 2025-05-12

Family

ID=83932014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568549A Pending JP2024516320A (ja) 2021-05-07 2022-05-06 Fc受容体への結合が改変されたFc変異体

Country Status (8)

Country Link
US (1) US20240228579A1 (cg-RX-API-DMAC7.html)
EP (1) EP4335868A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516320A (cg-RX-API-DMAC7.html)
CN (1) CN117295760A (cg-RX-API-DMAC7.html)
AU (1) AU2022269145B2 (cg-RX-API-DMAC7.html)
CA (1) CA3218187A1 (cg-RX-API-DMAC7.html)
TW (1) TWI839729B (cg-RX-API-DMAC7.html)
WO (1) WO2022233320A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024333211A1 (en) * 2023-08-30 2026-03-19 Astellas Pharma Inc. Fc REGION VARIANT

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
EP3342782B1 (en) * 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
TW201245227A (en) * 2011-03-29 2012-11-16 Roche Glycart Ag Antibody Fc variants
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
ES2597228T3 (es) * 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
KR20180087430A (ko) * 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
EP3494139B1 (en) * 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
US12024560B2 (en) * 2017-03-28 2024-07-02 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
CN112912395B (zh) * 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法

Similar Documents

Publication Publication Date Title
EP3356420B1 (en) Multispecific antibodies
JP2021007390A5 (cg-RX-API-DMAC7.html)
EP3174897B1 (en) Multispecific antibodies
ES2534313T3 (es) Anticuerpos anti-CXCR4 para el tratamiento del VIH
JP2021533779A5 (cg-RX-API-DMAC7.html)
JP2007530435A5 (cg-RX-API-DMAC7.html)
EP3027649B1 (en) Tnfa-il-17 bispecific antibodies
JP2021019598A (ja) Fc含有ポリペプチドの安定化
JP2022504550A5 (cg-RX-API-DMAC7.html)
JP2022512043A5 (cg-RX-API-DMAC7.html)
JP2024521472A5 (cg-RX-API-DMAC7.html)
RU2007129676A (ru) Антитела к рецептору альфа 1 il-13 и их применение
CA2376485A1 (en) Recombinant anti-cd40 antibody and uses thereof
JP2023015301A5 (cg-RX-API-DMAC7.html)
JP2022534135A5 (cg-RX-API-DMAC7.html)
HRP20230590T1 (hr) Novi fuzijski protein specifičan za cd137 i pd-l1
JP2002500043A5 (cg-RX-API-DMAC7.html)
JP2023530663A5 (cg-RX-API-DMAC7.html)
JP2018513149A (ja) Cd38に結合する抗体治療剤
JP2018512124A5 (cg-RX-API-DMAC7.html)
JPWO2022224997A5 (cg-RX-API-DMAC7.html)
CN1381461A (zh) 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用
CN114127126A (zh) ETA抗体与TGF-βTrap的融合蛋白质,以及其药物组合物和应用
IL145676A (en) Tumor necrosis factor homologs and nucleic acids encoding the same
JP2023171909A5 (cg-RX-API-DMAC7.html)